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Working with Vassa Informatics
 Founded (2007) to develop information-theory based 
technologies that would provide additional tools for 
scientists studying the functional effects of differences 
between similar nucleotide and amino acid sequences
 BioVassa was the initial result of this work
 Collaborations with Indiana University-Northwest, Washington 
University - St. Louis and the University of Chicago further 
refined BioVassa
 ChemVassa applies information content analysis to 
chemical sequences of arbitrary length with an eye 
towards small molecule screening for drug discovery
 Development and initial proof of concept work complete
Information Content Overview
Information 
content is a 
measurement 
of a unit’s 
(e.g., a small 
molecule) 
compressabili
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 We can present this information graphically in several ways; the 
important point (looking at Conotoxin, PDB: 1AS5 is that we are 
generally tracking binding or interaction sites.
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 ChemVassa works by calculating the information content of a molecule, 
utilizing spatial information (taken from PDB, converted SMILES, or 
other structural information files) to locate an atom within the molecule
 Each atom is converted using a lexicon that accounts for the valence 
shell content, atomic number, and reactivity of the atom
The location of each atom is then compared and the reactivity between 
ChemVassa Overview

adjacent atoms is compared
 The average of the distance multiplied by the reactivity difference is the “G 
score”
 G scores for the backbone of the molecule are calculated as follows:
 The average for connected non-main-chain molecules is added to the connected main 
carbon atom and summed across the backbone and averaged; this is the “M score”
 A string of G scores may then be searched across a database of 
compounds
Test Molecule: Lipitor
ChemVassa Validation
Is ChemVassa able to predict 
novel binding partners for a 
Question:
chemical ligand that cannot be 
predicted by existing methods ab 
initio?
Lipitor
• Lipitor was chosen as:
• Commercially valuable
• Crystal structures of HMG-CoA reductase 
in complex with six statins are available 
• All marketed HMG CoA reductase 
inhibitors are structurally similar – can we 
identify novel scaffolds and chemistry?
Lipitor Structure
Lipitor works by binding to and inhibiting the liver 
enzyme HMG-CoA reductase
Lipitor
VaSSA Analysis - Lipitor
 Red Regions are high 
information content
 Blue regions are low
 ChemVassa correctly 
identified the binding 
region where Lipitor 
interacts with its 
target (Hmg-CoA 
reductase) and 
predicts most of the 
important interacting 
atoms that were 
determined 
experimentally
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Slide 9
LK1 is "most of the important interacting atoms..." the best way to say this?
Lisa Kenney, 1/29/2010
LK2 This should go on the Results slide (as written).
I think this third bullet should provide additiona analysis information or explanation
Lisa Kenney, 1/29/2010
Results
 We searched a 600,000 ligand library using the 
Lipitor information signature
 We categorized the results as: Positive 
(Validation), Known Binders (Neutral), False 
Positive, or Novel
 Of these results, about 60% were known binders 
or novel results; 40% were false positives
 We found 10 Novel, previously unknown  results 
which can be tested for functionality at the bench
 These novel compounds would not be able to be 
identified utilizing existing methods
LK3
LK4
Slide 10
LK3 I rewrote this and it still isn't quite right. Theoretically, we should provide the breakdown by category...
Lisa Kenney, 1/29/2010
LK4 Are Known Binders Neural, or are they validation?
Lisa Kenney, 1/29/2010
Positive (Validation) Results
 We utilized the search to see if it would identify 
other statins
 Creating a statin library, we reliably pulled 
statins as results if the binding region was 
used as search input
 This shows that there is a shared set of 
physical properties that ChemVassa is able to 
detect within the statins
Known Binders (Neutral)
 In some cases, we pulled results that were not statins 
and NOT structurally similar to lipitor that, however, 
are known binders of HmG-CoA Reductase. 
 An example is Coenzyme A; it was returned as a 
search result though it is NOT structurally similar to 
Lipitor.
 However, as CoA binds HmG-CoA reductase, it is 
NOT a negative result and suggested that the 
algorithm is tracking a FUNCTIONAL property of 
HmG-CoA reductase binding, NOT just a physical 
one.
False Positives
 Of course, we also returned some results that do NOT 
bind HmG-Coenzyme A reductase and are NOT 
structurally similar to Lipitor. 
 An example is Vancomyacin; it was returned as a 
search result though it is NOT structurally similar to 
Lipitor and DOES NOT bind HmG-CoA reductase.
 These results fell into two categories; complete non-
binders, and cases where a portion of the molecule 
would likely bind except cannot due to steric 
hindrance.
 About 40% of the experimental search results fell into 
this category.
Novel Results
 These results are not structurally similar to Lipitor, but that appear 
to be capable of binding HmG-CoA reductase in a manner similar 
to Lipitor
 Modeling allowed us to look at affinity and electrostatic contacts of 
these results
 About 40% of the experimental search results fell into this 
category, most with exceptionally good binding.
 These included some hits where little biological information was 
present, and cases where biological information provided insight 
into the possible mechanism for the ligand function
 Currently, VaSSA Informatics is utilizing these results for 
partnership development with several interested parties.
Additional Results
G2L AVS
Glu:559
Y
G2L (3'-o-methyoxyethyl-guanosine-5'-monophosphate ) also interacts with the 
Hmg-CoA reductase site. Although the compound is not well-studied, it is small 
and should be bio-accessible.
Arg:590
Y*
Leu:658
N
Ser:684
Y*
Asp:690
N
Lys:692
Y*
Lys:735 Y*
Ala:751
Y*
Leu:853
Y*
YES, our models show that 
ChemVassa can ab initio* predict 
Answer:
novel binding partners for chemical 
ligands that cannot be predicted by 
existing methods.
Cost Model Discussion
How are we moving forward?
 Develop a compound library of about 9 million 
compounds, including about 1.5 million 
“sweet-spot” that have good drug-like qualities.
 Developing the infrastructure for this quickly 
and on a limited budget for deployment, we 
explored several options:
 Server purchase
 Machine rental
 Cloud services
Cloud computing
 We have two tasks:
 Initial candidate screening, using ChemVaSSA to 
generate a compound library and screen the 
library
Modeling the results to see if they are compatible 
with binding.
 Project-based pricing
Creating the library: about $300.
Screening the library: about $30 per compound.
Modeling the results: about $55 per 1000 models.
Conclusions
 Cloud computing may work for initial 
development of computing infrastructure.
Not ideal for all cases
 Allows accurate prediction of project times
 Allows quick set-up/tear down of infrastructure
 Costs can be billed back to a source (grant, 
client, etc)
 Low overhead.
Future Directions
 Cloud computing for development of 
Bioinformatic teaching infrastructure
 Non-persistant nature of facilities fits well with 
semester-to-semester changes in enrollment.
 Cost basis can be readily understood.
 Limiting student access to ensure effective use of 
resources
 Development of trial web-based resources for 
grants and exploratory research.
